Paradigm Biopharmaceuticals Ltd.ASX: PAR

First patient dosed in mps-i phase 2 clinical trial

Nov 12, 2020 at 2:40 AM UTC · Issued by Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd has released a press release.

View Attachment